Table 6. List of the FFPE and matching normal samples of the ten ovarian cancer patients included in this test.
| Case nr. | Tissue type | Mutational status |
|---|---|---|
| 1 | Normal FFPE | WT |
| Tumor FFPE-50% | WT | |
| 2 | Periph. blood | WT |
| Tumor FFPE-30% | WT | |
| 3 | Periph. blood | WT |
| Tumor FFPE-60% | WT | |
| 4 | Periph. blood | WT |
| Tumor FFPE-80% | WT | |
| 5 | Periph. blood | WT |
| Tumor FFPE-60% | WT | |
| 6 | Periph. blood | WT |
| Tumor FFPE-60% | WT | |
| 7 | Periph. blood | WT |
| Tumor FFPE-80% | BRCA1: p.Q210* | |
| 8 | Normal FFPE | BRCA1: p.Ser1755?fs |
| Tumor FFPE-80% | BRCA1: p.Ser1755?fs | |
| 9 | Periph. blood | BRCA1: p.Ser1755?fs |
| Tumor FFPE-30% | BRCA1: p.Ser1755?fs | |
| 10 | Periph. blood | BRCA1: p.R1751* |
| Tumor FFPE-70% | BRCA1: p.R1751* |
Tumor cell percentage in FFPE samples was estimated visually by molecular pathologist. Lymphocyte DNA isolated from peripheral blood was originally used as a default reference normal DNA, however, in some cases this was not possible and thus was replaced by FFPE DNA from non-tumorous regions of the tissue-slide. Mutational status of the samples determined by NGS is also illustrated. Detailed list of mutations and neutral variants found in these 10 sample-pairs can be found in Supplementary Table S2.